News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Accium BioSciences, Inc. Takes $3 Million Series A
January 6, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Accium BioSciences, a provider of bioanalytical services with a focus on early-stage drug development, has raised $3 million in a Series A round.
Twitter
LinkedIn
Facebook
Email
Print
Startups
MORE ON THIS TOPIC
diabetes
Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns
April 16, 2026
·
2 min read
·
Gabrielle Masson
Insights
Can Europe turn world-class science into world-class scale?
April 16, 2026
·
5 min read
·
Jennifer C. Smith-Parker
Funding
Revolution doubles stock offering target to $2B following pancreatic cancer win
April 16, 2026
·
1 min read
·
Tristan Manalac
Artificial intelligence
Novartis CEO joins Anthropic board, embedding AI in the heart of biopharma
April 16, 2026
·
2 min read
·
Tristan Manalac
